

Effect of a Lung Protective Strategy for Organ Donors on Eligibility and Availability of Lungs for Transplantation

A Randomized Controlled Trial

Luciana Mascia, MD, PhD

Daniela Pasero, MD

Arthur S. Slutsky, MD

M. Jose Arguis, MD

Maurizio Berardino, MD

Salvatore Grasso, MD

Marina Munari, MD

Silvia Boifava, MD

Giuseppe Cornara, MD

Francesco Della Corte, MD

Nicoletta Vivaldi, MD

Paolo Malacarne, MD

Paolo Del Gaudio, MD

Sergio Livigni, MD

Elisabeth Zavala, MD

Claudia Filippini, PhD

Erica L. Martin, PhD

Pier Paolo Donadio, MD

Ilaria Mastromauro, MD

V. Marco Ranieri, MD

PATIENTS WITH RELATIVELY NORMAL pulmonary function at the time of brain death may have declines in functioning, and only 15% to 20% of these patients' lungs are subsequently suitable for transplantation.¹⁻³ This may result from the pulmonary damage associated with brain injury⁴ or the iatrogenic effects of mechanical ventilation.^{5,6}

See also pp 2592 and 2643 and Patient Page.

Context Many potential donor lungs deteriorate between the time of brain death and evaluation for transplantation suitability, possibly because of the ventilatory strategy used after brain death.

Objective To test whether a lung protective strategy increases the number of lungs available for transplantation.

Design, Setting, and Patients Multicenter randomized controlled trial of patients with beating hearts who were potential organ donors conducted at 12 European intensive care units from September 2004 to May 2009 in the Protective Ventilatory Strategy in Potential Lung Donors Study.

Interventions Potential donors were randomized to the conventional ventilatory strategy (with tidal volumes of 10-12 mL/kg of predicted body weight, positive end-expiratory pressure [PEEP] of 3-5 cm H₂O, apnea tests performed by disconnecting the ventilator, and open circuit for airway suction) or the protective ventilatory strategy (with tidal volumes of 6-8 mL/kg of predicted body weight, PEEP of 8-10 cm H₂O, apnea tests performed by using continuous positive airway pressure, and closed circuit for airway suction).

Main Outcome Measures The number of organ donors meeting eligibility criteria for harvesting, number of lungs harvested, and 6-month survival of lung transplant recipients.

Results The trial was stopped after enrolling 118 patients (59 in the conventional ventilatory strategy and 59 in the protective ventilatory strategy) because of termination of funding. The number of patients who met lung donor eligibility criteria after the 6-hour observation period was 32 (54%) in the conventional strategy vs 56 (95%) in the protective strategy (difference of 41% [95% confidence interval {CI}, 26.5% to 54.8%]; $P < .001$). The number of patients in whom lungs were harvested was 16 (27%) in the conventional strategy vs 32 (54%) in the protective strategy (difference of 27% [95% CI, 10.0% to 44.5%]; $P = .004$). Six-month survival rates did not differ between recipients who received lungs from donors ventilated with the conventional strategy compared with the protective strategy (11/16 [69%] vs 24/32 [75%], respectively; difference of 6% [95% CI, -22% to 32%]).

Conclusion Use of a lung protective strategy in potential organ donors with brain death increased the number of eligible and harvested lungs compared with a conventional strategy.

Trial Registration clinicaltrials.gov Identifier: NCT00260676

JAMA. 2010;304(23):2620-2627

www.jama.com

There is evidence in various settings demonstrating that a lung protective strategy is beneficial. In patients with acute lung injury, ventilation

Author Affiliations are listed at the end of this article.
Corresponding Author: V. Marco Ranieri, MD, Department of Anesthesia, University of Turin, San Giovanni Battista Molinette Hospital, Corso Dogliotti 14, Turin 10126, Italy (marco.ranieri@unito.it).

with low tidal volumes decreased absolute mortality by 9%.⁷ In patients with normal pulmonary function, ventilation with lower tidal volumes was associated with a lower likelihood of developing acute lung injury.⁸ In patients with brain injuries, ventilation with higher tidal volumes was an independent factor contributing to development of acute lung injury.⁶

Despite this evidence, there is controversy as to the best ventilatory strategy to use in patients diagnosed as having brain death. A consensus conference⁹ recommended ventilation with low tidal volumes of 10 to 12 mL/kg of measured body weight and positive end-expiratory pressure (PEEP) of 5 cm H₂O. A subsequent review article¹⁰ and an observational study¹¹ suggested that potential donors should receive ventilation with low tidal volumes of 8 to 10 mL/kg of predicted body weight. Guidelines for potential organ donors currently recommend ventilation with higher levels of low tidal volume (10-15 mL/kg of measured body weight).^{12,13}

We hypothesized that a protective lung strategy in patients diagnosed as having brain death would decrease the development of lung dysfunction and increase the number of lungs available for transplantation.

METHODS

Potential donors were from 12 intensive care units in Italy and Spain, had normal heart beat patterns, and had been reported to organ procurement organizations between September 2004 and May 2009. The ethics review boards of all of the participating hospitals approved the protocol and relatives of the patients provided consent for organ donation. Exclusion criteria were denied consent for organ donation; legal issues preventing organ donation; history of cardiac arrest; age younger than 18 years or older than 65 years; radiographic pulmonary infiltrates; duration of mechanical ventilation until brain death longer than 5 days; smoking history (>20 pack-years), asthma or chronic obstructive pulmonary disease, chest trauma or previous tho-

racic surgery; and aspiration pneumonia or purulent secretions diagnosed by bronchoscopy, sputum, or bronchoalveolar lavage positive for Gram stain, fungus, or white blood cells.^{3,14,15}

The Protective Ventilatory Strategy in Potential Lung Donors Study used a central Web site that created a concealed, computer-generated block randomization schedule that assigned patients to either the conventional or protective lung ventilatory strategy, which was applied during the observation period required for declaration of brain death (6 hours), and maintained until patients arrived in the operating department for organ extraction.

In the conventional strategy, patients received ventilation with low tidal volumes of 10 to 12 mL/kg of predicted body weight⁷ and PEEP of 3 to 5 cm H₂O.² An open circuit was used for tracheal suction. Apnea tests were performed by disconnecting the patient from the ventilator while administering high-flow oxygen.

In the protective strategy, patients received ventilation with low tidal volumes of 6 to 8 mL/kg of predicted body weight and PEEP of 8 to 10 cm H₂O. A closed circuit was used for tracheal suction.¹⁶ Apnea tests were performed with the ventilator in the continuous positive airway pressure mode.¹⁷ Continuous positive airway pressure was set equal to the previous PEEP used during mechanical ventilation. Recruitment maneuvers (doubling ventilation with low tidal volumes for 10 breaths)¹⁸ were performed after any disconnection from the ventilator.


In both strategy groups, respiratory rate was adjusted to obtain PaCO₂ of 40 to 45 mm Hg and fraction of inspired oxygen (FIO₂) was adjusted to obtain PaO₂ of 90 mm Hg or greater. The viability of lungs was assessed at the beginning and at the end of the 6-hour observation period.^{3,14} The ratio of PaO₂ to FIO₂ and peak airway pressure at the end of the 6-hour observation period were reported to the organ procurement organization.^{3,14} The officer of the organ procurement organization was not aware of patient allocation and was

not involved in the study. The officer of the organ procurement organization declared the potential donor as eligible for harvesting of the lungs when the ratio of PaO₂ to FIO₂ was 300 mm Hg or greater, FIO₂ was 1.0, and peak airway pressure was less than 30 cm H₂O.^{3,14} The officer of the organ procurement organization then reported the potential lung donor to the lung transplant surgeon who, after examining the potential donor, made the final decision on the suitability of the lungs.

The surgeon was blinded to patient allocation and was not otherwise involved in the study. The reasons given by the lung transplant surgeon not to harvest lungs were prospectively classified as (1) lung donor issues (functional lungs that at the moment of harvest no longer met oxygenation and peak airway pressure criteria for eligibility; infectious, clinical, radiological, or laboratory manifestation of pulmonary infection occurring after diagnosis of brain death; or pulmonary contusions observed during inspection of the lungs with the chest open) and (2) lung recipient issues (donor-recipient incompatibility, lack of potential recipients matching size, blood group, or human leukocyte antigen compatibility; or logistical [inability of the surgical team to proceed in time for harvest, collection, and transplantation]). The number of harvested hearts, livers, and kidneys in both groups was recorded.

The primary outcome of the study was the number of potential donors meeting eligibility criteria for lung harvest at the end of the 6-hour observation period. Other clinical outcomes were the number of lungs harvested and the number of patients who received lung transplants who were alive at 6 months.

Six-month survival also was recorded for patients who received other organs harvested from the donors. Duration of intensive care unit stay was recorded in lung transplant recipients. Blood samples were collected at the beginning and at the end of the 6-hour ob-

Figure. Assessment of Eligibility and Inclusion in the Protective Ventilatory Strategy in Potential Lung Donors Study

servation period for measurements of IL-1 β , IL-1 receptor antagonist, IL-6, IL-8, tumor necrosis factor, and tumor necrosis factor receptors I and II.⁵

In a previous observational study,² we found that 54% of potential lung donors met eligibility criteria for lung donation. Based on this, the study was powered for 200 patients to demonstrate a 25% absolute increase in eligible lungs (from 50% to 75%), with a 5% risk of type I error, and a power level of 90%. An interim analysis was planned after data were obtained on the first 100 patients. The stopping boundaries of the study were based on the primary end point and were designed to allow termination of the study if the protective strategy was better than the conventional (control) strategy ($P < .003$) or for futility ($P > .03$).¹⁹

All analyses were conducted on an intention-to-treat basis. Data are presented as mean (SD) or median (interquartile range [IQR]). Comparisons between groups and within groups were made using the *t* test, the Wilcoxon rank sum test, the χ^2 test, the Fisher exact test, and the McNemar test. All tests were 2-tailed. The primary outcome also was evaluated using multivariate logistic regression analyses. To exam-

ine the temporal effect across groups during the 6-hour observation period, relevant clinical variables were analyzed using a mixed-linear regression model for repeated measures in which each parameter was the dependent variable, while time and group were the independent variables. The number needed to treat to benefit also was estimated (ie, the number of patients with brain death who had to be treated with the protective strategy to obtain an extra lung donor who met acceptability criteria). Results are reported as odds ratios (ORs) with 95% confidence intervals (CIs). To account for individual hospital effects, the cumulative OR was used as a measure of effect size in a robust logistical regression model. The level of statistical significance was set at .05. Statistical analysis was conducted using SAS software version 9.2 (SAS Institute Inc, Cary, North Carolina).

RESULTS

The steering committee stopped the Protective Ventilatory Strategy in Potential Lung Donors Study before the planned interim analysis was performed because of termination of funding. The steering committee did not

have knowledge of the clinical outcomes at the time this decision was made.

Of the 918 potential organ donors reported to the organ procurement organization, 118 patients were randomized and included in the final analysis. Denied consent, legal issues, and cardiac arrest were the reasons for excluding 355 patients (39%). The remaining 445 patients (42%) were excluded based on the standard criteria³ used to identify nonoptimal lungs (FIGURE). There were no missing data and no patients were lost to follow-up.

Baseline characteristics were similar in both groups (TABLE 1). After randomization, ventilation with low tidal volume was lower and respiratory rate, PEEP, and central venous pressure were higher in the protective strategy compared with the conventional strategy. The ratio of PaO₂ to FiO₂ was higher in the protective strategy compared with the conventional strategy at the third and sixth hour of the observation period (TABLE 2).

At study enrollment, the number of patients who met eligibility criteria did not differ between the conventional strategy and the protective strategy. At the end of the 6-hour period, the number of patients meeting lung donor eligibility criteria decreased in the conventional strategy from 49 (83%) to 32 patients (54%) (difference of 29% [95% CI, 12% to 46%]; $P = .001$). The number of patients meeting lung donor eligibility criteria at the end of the 6-hour period increased slightly in the protective strategy from 51 (86%) to 56 patients (95%) (difference of 9% [95% CI, -2.1% to 19.1%], $P = .13$). The number of patients in the conventional strategy who met lung donor eligibility criteria at the end of the 6-hour observation period was 32 (54%) compared with 56 (95%) in the protective strategy (difference of 41% [95% CI, 26.5% to 54.8%]; $P < .001$) (TABLE 3). The number of patients in whom lungs were harvested was 16 (27%) in the conventional strategy compared with 32 (54%) in the protective strategy

(difference of 27% [95% CI, 10.0% to 44.5%]; $P=.004$).

Multivariate and regression logistic analyses showed that eligibility at the end of the 6-hour observation period was associated with the protective strategy (OR, 25.4 [95% CI, 5.6-114.6]; $P=.001$) and with use of vasoactive drugs at randomization (OR, 4.3 [95% CI, 1.2-16.0]; $P=.02$). The number needed to treat to benefit was 3.0 (95% CI, 1.8-3.7). Sixteen patients (50%) in the conventional strategy compared with 24 patients (43%) in the protective strategy (difference of 7% [95% CI, 0%-29.3%]; $P=.52$) met lung donor eligibility criteria at the end of the 6-hour observation period but their lungs were rejected by the surgeon for subsequent transplantation (Table 3). We did not find any individual hospital effect when cumulative OR was used as a measure of effect size in a robust logistical regression model.

The number of patients classified as not meeting eligibility criteria by the blinded officer of the organ procurement organization was 27 in the conventional strategy and 3 in the protective strategy at the end of the eligibility test, which lasted a median of 38 minutes (IQR, 25 to 40 minutes). Patients had a ratio of PaO_2 to FiO_2 of 208 (83) in the conventional strategy and 224 (47) in the protective strategy (difference of proportion, 16; 95% CI, -86 to 116) and a peak airway pressure of 31 (5) cm H₂O in the conventional strategy and 34 (6) cm H₂O in the protective strategy (difference of proportion, 3; 95% CI, -2.9 to 9.1).

The number of patients classified as meeting eligibility criteria by the blinded officer of the organ procurement organization was 32 in the conventional strategy and 56 in the protective strategy at the end of the eligibility test, which lasted a median of 33 minutes (IQR, 20 to 43 minutes). Patients had a ratio of PaO_2 to FiO_2 of 454 (76) in the conventional strategy and 491 (115) in the protective strategy (difference of proportion, 37; 95% CI, -8 to 82) and a peak airway

pressure of 26 (4) cm H₂O in the conventional group and 25 (4) cm H₂O in the protective group (difference of proportion, 1; 95% CI, -0.5 to 3.2). None of these differences was statistically significant.

The median length of mechanical ventilation from the end of the 6-hour observation period to the moment of organ harvest was 6 hours (IQR, 3-16 hours) in the conventional strategy and 4 hours (IQR, 3-18 hours) in the protective strategy. During this period, the ventilator settings selected at randomization were maintained for all patients.

The median intensive care unit length of stay for patients who received lungs from donors in the conventional strategy was 12 days (IQR, 1 to 100 days) compared with 8 days (IQR, 2 to 100 days) for patients who received lungs from donors in the protective strategy. The 6-month survival rate was 69% (11/16) for patients who received lungs from donors in the conventional strategy compared with 75% (24/32) for patients who received lungs from donors in the protective strategy (difference of 6%; 95% CI, -22% to 32%). The number of other organs harvested did not differ between the con-

Table 1. Patient Characteristics at Enrollment

	Ventilatory Strategy	
	Conventional (n = 59)	Protective (n = 59)
Age, mean (SD), y	45 (13)	42 (13)
Female sex, No. (%)	27 (46)	34 (58)
Primary diagnosis, No. (%)		
Traumatic brain injury	17 (29)	12 (20)
Cerebrovascular hemorrhagic accident	37 (63)	45 (76)
Other ^a	5 (8)	2 (3)
Duration of mechanical ventilation prior to randomization, median (IQR), h	38 (6-120)	34 (2-120)
Ventilatory pattern, mean (SD)		
FiO_2	45 (12)	44 (11)
Tidal volume, mL/kg of predicted body weight	9.3 (1.5)	9.0 (1.6)
Respiratory rate, breaths/min	13 (3)	13 (2)
PEEP, cm H ₂ O	4.3 (2.9)	5.0 (2.8)
Peak inspiratory pressure, cm H ₂ O	21 (5)	22 (4)
Plateau pressure, cm H ₂ O	16 (3)	16 (4)
Minute ventilation, L/min	7.2 (1.9)	7.0 (1.7)
Ratio of PaO_2 to FiO_2	393 (144)	400 (124)
Arterial blood gases, mean (SD)		
PaO_2 , mm Hg	171 (112)	173 (74)
SaO_2 , %	98 (2)	99 (1)
PaCO_2 , mm Hg	36 (5)	36 (6)
Arterial pH	7.44 (0.07)	7.43 (0.07)
Hemodynamic variables, mean (SD)		
Mean arterial pressure, mm Hg	84 (16)	83 (16)
Central venous pressure, mm Hg	6.4 (2.9)	7.5 (2.8)
Vasoactive drug use	47 (80)	47 (80)
Concomitant treatment ^b		
Dopamine, median (IQR), $\mu\text{g/kg/min}$	7.5 (1-15)	6.5 (0.9-17)
Norepinephrine, median (IQR), $\mu\text{g/kg/min}$	0.13 (0.02-0.25)	0.16 (0.02-0.30)
Prednisolone, No. (%)	10 (17)	12 (20)
Triiodothyronine or thyroxine, No. (%)	9 (15)	8 (14)
Vasopressin, No. (%)	2 (3)	1 (2)

Abbreviations: FiO_2 , fraction of inspired oxygen; IQR, interquartile range; PEEP, positive end-expiratory pressure; SaO_2 , arterial oxygen saturation.

^aSuch as for ischemic stroke.

^bEighteen patients in each group received dopamine and norepinephrine in combination.

ventional strategy and the protective strategy (hearts: 25 [42%] vs 28 [47%], respectively, difference of 5% [95% CI, -13% to 23%]; livers: 48 [81%] vs 52 [88%], difference of 7% [95% CI, -6.4% to 19.9%]; kidneys: 83 [70%] vs 94 [80%], difference of 10% [95% CI, -1.8% to 20.4%]). Six-month survival did not differ between patients who received other organs from donors in the conventional strategy and the protective strategy (hearts: 70% vs 80%, respectively, difference of 10% [95% CI, -15% to 36%]; liver: 94% vs 94% difference of 0% [95% CI, -0.11% to 0.08%]; kidneys: 95% vs 94%, difference of 1% [95% CI, -0.06% to 0.07%]).

Blood samples were obtained in 20 patients in the conventional strategy and in 17 patients in the protective strategy. Cytokine concentrations at baseline were similar in both groups (TABLE 4). A significant increase over time in IL-6 and tumor necrosis factor receptors was observed in the conventional group ($P < .01$), but not in the protective group; all other measured cytokines did not change over time.

COMMENT

This study demonstrates that a lung protective strategy in potential organ donors resulted in a higher number of eligible donors and harvested lungs compared with a conventional strategy. Of importance, the number of harvested hearts, livers, and kidneys did not differ between the conventional and protective strategies.

An interim analysis, performed by an independent data and safety monitoring board was planned after data were obtained on the first 100 patients. The steering committee, however, stopped the trial prior to the planned interim analysis because accrual had been slow, and all of the funding for the trial had been spent.

Patient No. 100 was randomized on September 30, 2008. The steering committee met to decide whether to ask the data and safety monitoring board to perform the interim analysis as planned by the statistical analysis plan or stop accrual and analyze all included patients as the final data set. Because supplementary funds had been requested, the

steering committee was unsure whether the study would proceed. It was decided to maintain the planned interim analysis to avoid the potential loss of α level and continue recruitment until responses from grant agencies were released (expected by spring 2009). On May 30, 2009, the steering committee was informed that sufficient extra funds to complete the study would not be provided. The steering committee decided (1) to halt the study and stop randomization, (2) to lock the database with patient No. 118 as the last patient (randomized on May 26, 2009), and (3) to analyze the data using the criteria that were prespecified for the final analysis. Of note, if the formal interim analysis had been performed, the data and safety monitoring board members may have stopped the trial at that point because the results crossed the predefined threshold for stopping for efficacy.

Early stopping for efficacy of randomized controlled trials may inflate the estimated treatment effect.²⁰ We believe this issue may not be relevant in

Table 2. Ventilatory and Hemodynamic Variables During the 6 Hours of Treatment

	Duration of Treatment and Ventilatory Strategy					
	First Hour		Third Hour		Sixth Hour	
	Conventional (n = 59)	Protective (n = 59)	Conventional (n = 59)	Protective (n = 59)	Conventional (n = 59)	Protective (n = 59)
Ventilatory variables, mean (SD)						
FiO ₂	47 (17)	42 (7)	48 (18)	44 (12)	50 (19)	44 (11)
Tidal volume, mL/kg of predicted body weight	10.1 (1.6)	7.9 (1.1) ^a	10.1 (1.6)	7.8 (1.0)	10.1 (1.7)	7.8 (1.0)
Respiratory rate, breaths/min	11 (2)	13 (3) ^a	11 (2)	14 (3)	11 (2)	14 (3)
PEEP, cm H ₂ O	4.2 (1.6)	8.7 (1.4) ^a	4.4 (1.5)	9.0 (1.4)	4.3 (1.6)	9.2 (1.8)
Peak inspiratory pressure, cm H ₂ O	22 (5)	23 (5)	23 (5)	23 (4)	22 (5)	23 (5)
Plateau pressure, cm H ₂ O	16 (4)	17 (4)	17 (4)	17 (3)	17 (4)	18 (4)
Minute ventilation, L/min	6.9 (1.5)	6.5 (1.7)	6.8 (1.8)	6.6 (1.8)	6.8 (1.7)	6.7 (1.9)
Ratio of PaO ₂ to FiO ₂	360 (120)	402 (118)	342 (126)	402 (129) ^b	332 (170)	396 (107) ^b
Blood gas analysis, mean (SD)						
PaO ₂ , mm Hg	164 (72)	166 (54)	165 (92)	176 (72)	156 (84)	169 (49)
SaO ₂ , %	99 (1)	99 (1)	98 (3)	99 (1)	98 (2)	99 (1)
PaCO ₂ , mm Hg	39 (7)	39 (6)	41 (8)	42 (5)	42 (10)	41 (5)
Arterial pH	7.42 (0.06)	7.41 (0.07)	7.41 (0.07)	7.39 (0.07)	7.40 (0.07)	7.39 (0.09)
Hemodynamic variables						
Mean arterial pressure, mean (SD), mm Hg	83 (14)	84 (15)	84 (15)	83 (14)	82 (16)	86 (17)
Central venous pressure, mean (SD), mm Hg	7.0 (2.7)	8.3 (2.9) ^b	6.5 (2.8)	8.2 (3.2)	7.0 (2.8)	8.5 (2.8)
Vasoactive drug use, No. (%)	49 (83)	47 (80)	49 (83)	46 (78)	50 (85)	44 (75)

Abbreviations: FiO₂, fraction of inspired oxygen; PEEP, positive end-expiratory pressure; SaO₂, arterial oxygen saturation.

^a $P < .001$ for comparison with conventional ventilatory strategy.

^b $P < .05$ for comparison with conventional ventilatory strategy using mixed-model linear regression for repeated measures.

the interpretation of our trial because the decision to stop early was made prior to the unblinding of outcomes by study group and before transmitting the data to the data and safety monitoring board.

In any randomized controlled trial, it is important to ensure that the control group represents a standard of care. We ensured this by basing the control strategy on a consensus conference recommendation that potential lung donors be ventilated with low tidal volumes of 10 to 12 mL/kg of measured body weight using a PEEP of 5 cm H₂O.⁹ In addition, prior to the current trial, we performed an observational study² that confirmed that the ventilatory strategy used after declaration of brain death was similar to these published recommendations. Despite a review article¹⁰ and an observational study¹¹ suggesting that potential lung donors should be ventilated with low tidal volumes of 8 to 10 mL/kg of predicted body weight, guidelines for the management of potential organ donors still recommend ventilation with low tidal volumes of 10 to 15 mL/kg of measured body weight and PEEP of 5 cm H₂O.^{12,13} These discrepancies persist because there has been no high-grade evidence demonstrating the superiority of any specific strategy for potential lung donors.^{10,21}

By their nature, the study interventions could not be blinded. To minimize potential bias, we assessed lung viability using well-accepted cutoffs for ratio of PaO₂ to FIO₂ and peak airway pressure obtained during fixed venti-

lator settings.^{3,14} These values were communicated to the organ procurement organizations, who then informed the transplant surgeon. The final decision to proceed to lung harvest was made by the transplant surgeon after examining the potential donor. Members of the organ procurement organization and surgeons were blinded to study group and not otherwise involved in the study.

All 918 consecutive patients diagnosed as having brain death were assessed for inclusion in the study. However, 39% were excluded for denied consent, legal issues, and cardiac arrest and 42% were excluded based on published criteria that identified nonideal lungs (Figure).³ Similarly to other clinical multiorgan donor programs,^{1,3} our randomized cohort rep-

resented 13% of eligible patients. It should be noted that transplant programs participating in the present study did not allow marginal donors (ie, patients whose lungs had relative contraindications such as age, smoking history, contusion, prolonged mechanical ventilation, etc).²²

Recent findings suggest that deterioration of lung function may be due to mechanisms directly related to brain death.^{23,24} We hypothesized that ventilation with low tidal volumes and higher PEEP levels would prevent the deterioration of lung function associated with brain death.²⁵ A number of lines of evidence support this hypothesis and the hypothesis that a lung protective strategy will decrease lung injury. First, animal data demonstrate that massive brain injury predisposes the

Table 3. End Points by Conventional and Protective Ventilatory Strategies

	Ventilatory Strategy, No. (%)		Difference of Percentage (95% CI)
	Conventional (n = 59)	Protective (n = 59)	
Met lung donor eligibility criteria			
At study inclusion	49 (83)	51 (86)	3 (−4.0 to 24.4)
6 h after randomization	32 (54) ^a	56 (95) ^b	41 (26.5 to 54.8)
Lungs harvested			
Yes	16 (27)	32 (54) ^c	27 (10.0 to 44.5)
No	16/32 (50) ^d	24/56 (43) ^d	7 (0 to 29.3)
Reasons lungs not harvested			
Functional	4 (25)	7 (29)	
Infectious	3 (19)	4 (17)	
Inspection	3 (19)	5 (21)	
Donor-receptant incompatibility	4 (25)	5 (21)	
Logistical	2 (12)	3 (12)	

Abbreviation: CI, confidence interval.

^aP<.001 using the McNemar test at study inclusion compared with 6 hours after randomization.

^bP=.001 for comparison with conventional ventilatory strategy using the Fisher exact test.

^cP=.004 for comparison with conventional ventilatory strategy using the χ^2 test.

^dValues expressed as number/total (percentage).

Table 4. Cytokines in the Conventional and Protective Ventilatory Strategies

	Conventional Ventilatory Strategy		Protective Ventilatory Strategy	
	At Baseline (n = 20)	At Sixth Hour (n = 20)	At Baseline (n = 17)	At Sixth Hour (n = 17)
Plasma concentration, median (interquartile range), pg/mL				
IL-1 β	0.24 (0.01-1.28)	0.52 (0.01-2.18)	0.35 (0.01-0.84)	0.28 (0.01-0.73)
IL-1 receptor antagonist	129 (97-686)	158 (84-562)	133 (71-672)	48 (7-539)
IL-8	17 (0.49-72)	18 (8-117)	16 (0.01-77)	14 (0.01-56)
IL-6	407 (31-3138)	1025 (282-4716) ^a	158 (13-3622)	259 (21-2620)
Tumor necrosis factor (TNF)	1.40 (0.10-22.0)	1.0 (0.10-15.0)	1.0 (0.01-15)	1.0 (0.01-14)
TNF receptor I	2571 (1083-5426)	4105 (3001-63351) ^a	2381 (923-4266)	2625 (1368-5185)
TNF receptor II	5245 (2011-10632)	8889 (6064-19323) ^a	4359 (2480-9673)	5187 (2392-9612)

^aP<.05 for comparison with baseline using paired t test on log₁₀-transformed values.

lung to ventilator-induced lung injury.²⁶ Second, application of a protective ventilatory strategy in an experimental model improved lung function after lung transplantation.²⁷ Third, observational studies demonstrated that ventilation with higher tidal volumes was an independent contributing factor for subsequent development of acute lung injury in patients with acute brain injury.⁶ Fourth, protective lung strategies in patients with relatively normal lungs decreased subsequent development of lung injury.⁸ Our results are in accord with these lines of evidence.

Prior to randomization, the number of patients who matched eligibility criteria did not differ between the conventional and protective strategies. At the end of the 6-hour period, the number of patients meeting lung eligibility criteria significantly decreased in the conventional strategy while they increased slightly in the protective strategy.

Our multifaceted lung protective intervention addressed 4 factors we hypothesized might affect lung preservation. We used ventilation with low tidal volumes, which improved outcomes in patients with acute lung injury,⁷ and decreased the development of acute lung injury.⁸ To prevent atelectasis, we used higher levels of PEEP, performed apnea tests using continuous positive airway pressure,¹⁷ used a closed system for tracheal suctioning,¹⁶ and used recruitment maneuvers after any disconnection from the ventilator.¹⁸

Which of these factors specifically improved respiratory functions is not certain. Ventilation with low tidal volumes of 10 to 12 mL/kg of predicted body weight may overstretch normal lungs in the presence of markedly decreased pulmonary compliance, which occurs in patients with severe acute lung injury.⁷ However, peak pressure and end-inspiratory plateau pressure ranged between 12 and 20 cm H₂O in both groups, values that are substantially lower than the recommended upper limit of 30 cm H₂O.²⁸ Under these circumstances, prevention of alveolar overstretch likely does not explain the

improvement of lung function observed in the protective strategy. On the other hand, recruitment of collapsed alveoli (obtained by application of recruitment maneuvers), prevention of end-expiratory collapse (obtained by the use of continuous positive airway pressure during the apnea test and of closed suctioning circuit), and maintenance of recruited alveoli (using higher levels of PEEP) may have prevented the pulmonary damage caused by ventilation at low tidal volumes.^{5,29}

In conclusion, our results suggest that the use of a lung protective strategy prevents the decline of pulmonary function consequent to brain death and roughly doubled the number of lungs available for transplantation.

Author Affiliations: Departments of Anesthesia and Intensive Care Medicine (Drs Mascia, Pasero, Filippini, Martin, Donadio, Mastromauro, and Ranieri), Neurology (Dr Berardino), and Emergency Medicine (Dr Del Gaudio), San Giovanni Battista Molinette Hospital, University of Turin, Turin, Italy; Division of Critical Care Medicine, Department of Medicine, University of Toronto, Toronto, Ontario, Canada (Dr Slutsky); Departments of Anesthesia and Intensive Care Medicine, Hospital Clinic, University of Barcelona, Barcelona, Spain (Drs Arguis and Zavala); Departments of Anesthesia and Intensive Care Medicine, Consorziale Policlinico Hospital, University of Bari, Bari, Italy (Dr Grasso); Departments of Anesthesia and Intensive Care Medicine, Azienda Hospital of Padova, University of Padua, Padua, Italy (Dr Munari); Departments of Anesthesia and Intensive Care Medicine, Azienda CTO Hospital, Turin, Italy (Dr Boifava); Departments of Anesthesia and Intensive Care Medicine, Azienda Santa Croce and Carle Hospital, Cuneo, Italy (Dr Cornara); Departments of Anesthesia and Intensive Care Medicine, Maggiore della Carità Hospital, University of Novara, Novara, Italy (Dr Della Corte); Departments of Anesthesia and Intensive Care Medicine, SS Antonio, Biagio, and Cesare Arrigo Hospital, Alessandria, Italy (Dr Vivaldi); Departments of Anesthesia and Intensive Care Medicine, Santa Chiara Hospital, Pisa, Italy (Dr Malacarne); and Departments of Anesthesia and Intensive Care Medicine, Giovanni Bosco Hospital, Turin, Italy (Dr Livigni).

Author Contributions: Dr Ranieri had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Mascia, Ranieri.

Acquisition of data: Mascia, Pasero, Arguis, Berardino, Grasso, Munari, Boifava, Cornara, Della Corte, Vivaldi, Malacarne, Del Gaudio, Livigni, Zavala, Donadio, Mastromauro, Ranieri.

Analysis and interpretation of data: Mascia, Pasero, Slutsky, Zavala, Filippini, Martin, Mastromauro, Ranieri.

Drafting of the manuscript: Mascia, Slutsky, Ranieri.

Critical revision of the manuscript for important intellectual content: Pasero, Arguis, Berardino, Grasso, Munari, Boifava, Cornara, Della Corte, Vivaldi, Malacarne, Del Gaudio, Livigni, Zavala, Filippini, Martin, Donadio, Mastromauro.

Statistical analysis: Mascia, Pasero, Filippini, Ranieri.

Obtained funding: Ranieri.

Administrative, technical, or material support: Pasero, Slutsky, Arguis, Berardino, Grasso, Munari, Boifava,

Cornara, Della Corte, Vivaldi, Malacarne, Del Gaudio, Livigni, Zavala, Martin, Donadio, Mastromauro.

Study supervision: Slutsky, Ranieri.

Financial Disclosures: None reported.

Funding/Support: The study was supported by grant VMR23a (2004-2006) from the Ministero della Salute, Programma Ricerca Finalizzata, grant CIPE LM002 (2005-2007) from the Regione Piemonte, Programma Ricerca Finalizzata, and grant VMRLM98 (2007-2010) from the Ministero dell'Università, Programmi di Ricerca di Interesse Nazionale.

Role of the Sponsor: The granting agencies had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.

Members of the Protective Ventilatory Strategy in Potential Lung Donors (POPS) Study Group: Rosario Urbino, Vincenzo Bonicalzi, Alberto Adduci (Ospedale S. Giovanni Battista-Molinette, Torino, Italy); Antonio Miletto, Chiara Pescarmone (Centro Traumatologico Ortopedico, Torino, Italy); Giorgio Iotti (Ospedale SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy); Donatella Isnardi (Ospedale Santa Croce e Carle, Cuneo, Italy); Paolo Navalesi, Laura Cancelliere, Maria Teresa Campailla (Ospedale Maggiore della Carità, Novara, Italy); Paolo Feltracco, Carlo Ori (Azienda Ospedaliera di Padova, Italy); Marzia Lorini (Ospedale Santa Chiara, Pisa, Italy); Tommaso Fiore, Francesco Bruno (Ospedale Consorziale Policlinico, Bari, Italy); Joseph Brugada (Hospital Clinic, Barcelona, Spain); and Carlo Alberto Castioni (Ospedale Giovanni Bosco, Torino, Italy).

Data and Safety Monitoring Board: Antonio Amoruso, MD, chair (Immunologia Trapianti, Università di Torino, Italy); Antonio Pesenti, MD (Anestesia e Rianimazione, Ospedale San Gerardo di Monza, University of Milano-Bicocca, Italy), and Franco Merletti, MD, PhD (Cancer Epidemiology Unit, CPO Piemonte, CeRMS, Università di Torino, Italy).

Steering Committee: Luciana Mascia, Claudia Filippini, Elisabeth Zavala, Arthur S. Slutsky, and V. Marco Ranieri.

REFERENCES

1. Ware LB, Wang Y, Fang X, et al. Assessment of lungs rejected for transplantation and implications for donor selection. *Lancet*. 2002;360(9333):619-620.
2. Mascia L, Bosma K, Pasero D, et al. Ventilatory and hemodynamic management of potential organ donors: an observational survey. *Crit Care Med*. 2006;34(2):321-327.
3. Van Raemdonck D, Neyrinck A, Verleden GM, et al. Lung donor selection and management. *Proc Am Thorac Soc*. 2009;6(1):28-38.
4. Mascia L, Sakr Y, Pasero D, Payen D, Reinhart K, Vincent JL; Sepsis Occurrence in Acutely Ill Patients (SOAP) Investigators. Extracranial complications in patients with acute brain injury: a post-hoc analysis of the SOAP study. *Intensive Care Med*. 2008;34(4):720-727.
5. Ranieri VM, Suter PM, Tortorella C, et al. Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome: a randomized controlled trial. *JAMA*. 1999;282(1):54-61.
6. Mascia L, Zavala E, Bosma K, et al; Brain IT group. High tidal volume is associated with the development of acute lung injury after severe brain injury: an international observational study. *Crit Care Med*. 2007;35(8):1815-1820.
7. Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. *N Engl J Med*. 2000;342(18):1301-1308.

8. Determann RM, Royakkers A, Wolthuis EK, et al. Ventilation with lower tidal volumes as compared with conventional tidal volumes for patients without acute lung injury: a preventive randomized controlled trial. *Crit Care*. 2010;14(1):R1.
9. Rosengard BR, Feng S, Alfrey EJ, et al. Report of the Crystal City meeting to maximize the use of organs recovered from the cadaver donor. *Am J Transplant*. 2002;2(8):701-711.
10. Wood KE, Becker BN, McCartney JG, D'Alessandro AM, Coursin DB. Care of the potential organ donor. *N Engl J Med*. 2004;351(26):2730-2739.
11. Angel LF, Levine DJ, Restrepo MI, et al. Impact of a lung transplantation donor-management protocol on lung donation and recipient outcomes. *Am J Respir Crit Care Med*. 2006;174(6):710-716.
12. United Network for Organ Sharing. Critical pathway for the organ donor. http://www.unos.org/docs/Critical_Pathway.pdf. Accessed October 2010.
13. Canadian Council for Donation and Transplantation. Organ donor management: survey of guidelines and eligibility criteria. <http://www.ccdt.ca/english/publications/background-pdfs/Organ-Donor-Guidelines.pdf>. Accessed October 4, 2010.
14. Trulock EP. Lung transplantation. *Am J Respir Crit Care Med*. 1997;155(3):789-818.
15. Frost AE. Donor criteria and evaluation. *Clin Chest Med*. 1997;18(2):231-237.
16. Maggiore SM, Lellouche F, Pigeot J, et al. Prevention of endotracheal suctioning-induced alveolar derecruitment in acute lung injury. *Am J Respir Crit Care Med*. 2003;167(9):1215-1224.
17. Squadrone V, Cocha M, Cerutti E, et al; Piedmont Intensive Care Units Network (PICUN). Continuous positive airway pressure for treatment of postoperative hypoxemia: a randomized controlled trial. *JAMA*. 2005;293(5):589-595.
18. Marini JJ. How best to recruit the injured lung? *Crit Care*. 2008;12(3):159.
19. Pocock SJ. Group sequential methods in the design and analysis of clinical trials. *Biometrika*. 1977;64:191-199.
20. Bassler D, Briel M, Montori VM, et al; STOPIT-2 Study Group. Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. *JAMA*. 2010;303(12):1180-1187.
21. Keegan MT, Coursin DB. An update on ICU management of the potential organ donor. In: Vincent JL, ed. *Yearbook of Intensive Care and Emergency Medicine*. New York, NY: Springer; 2010.
22. Gabbay E, Williams TJ, Griffiths AP, et al. Maximizing the utilization of donor organs offered for lung transplantation. *Am J Respir Crit Care Med*. 1999;160(1):265-271.
23. Kalsotra A, Zhao J, Anakk S, Dash PK, Strobel HW. Brain trauma leads to enhanced lung inflammation and injury: evidence for role of P4504Fs in resolution. *J Cereb Blood Flow Metab*. 2007;27(5):963-974.
24. Fisher AJ, Donnelly SC, Hirani N, et al. Elevated levels of interleukin-8 in donor lungs is associated with early graft failure after lung transplantation. *Am J Respir Crit Care Med*. 2001;163(1):259-265.
25. Matuschak GM. Optimizing ventilatory support of the potential organ donor during evolving brain death: maximizing lung availability for transplantation. *Crit Care Med*. 2006;34(2):548-549.
26. López-Aguilar J, Villagrà A, Bernabé F, et al. Massive brain injury enhances lung damage in an isolated lung model of ventilator-induced lung injury. *Crit Care Med*. 2005;33(5):1077-1083.
27. de Perrot M, Imai Y, Volgyesi GA, et al. Effect of ventilator-induced lung injury on the development of reperfusion injury in a rat lung transplant model. *J Thorac Cardiovasc Surg*. 2002;124(6):1137-1144.
28. Gattinoni L, Caironi P, Cressoni M, et al. Lung recruitment in patients with the acute respiratory distress syndrome. *N Engl J Med*. 2006;354(17):1775-1786.
29. Tremblay L, Valenza F, Ribeiro SP, Li J, Slutsky AS. Injurious ventilatory strategies increase cytokines and c-fos m-RNA expression in an isolated rat lung model. *J Clin Invest*. 1997;99(5):944-952.

He only has known the full joy of living who somewhere and at some time has struck a decisive blow for the freedom of the human spirit.

—Walter Lippmann (1889-1974)

Improving the Supply of Donor Organs

Being Careful With the Gift of Life

Mark S. Roberts, MD, MPP

DONOR ORGANS ARE A VALUABLE BUT SCARCE resource that provide a lifesaving procedure to thousands of patients per year. However, the demand for organs of all types far exceeds supply. In 2009, 50 463 patients were added to the United Network for Organ Sharing's wait list, 28 463 patients received an organ transplant, and 6683 patients died while waiting for a suitable organ.¹ Despite substantial effort and research devoted to improving donation rates in the United States, these rates remain substantially lower than those in many other developed countries.² Many techniques such as implied consent, opt-out policies,³ breakthrough collaborative and quality improvement methods,⁴ and financial incentives^{5,6} have been proposed to expand the pool of organ donors.

Two articles^{7,8} in this issue of *JAMA* present important information about this problem and provide simultaneously sobering and encouraging insights into strategies to improve the supply of organs.

The randomized controlled trial by Mascia and colleagues⁸ compared the conventional ventilatory method used for potential lung donors with a lung preservation (protective) strategy from the time of brain death. The protective strategy included lower tidal volumes, higher positive end-expiratory pressure, alveolar recruitment maneuvers after any ventilator disconnection, and the use of continuous positive airway pressure during apnea tests. This study breaks important new ground in providing a solid evidence base for the care of potential organ donors and testing techniques of organ preservation. The surgeons evaluating the organs for transplant suitability were blinded to the ventilation strategy (conventional vs protective) and all outcomes (including organ donations other than the lung) were followed up.

The results of the study are profound. The protective strategy nearly doubled the number of eligible lungs at 6 hours (32 patients [54%] in the conventional strategy vs

56 patients [95%] in the protective strategy) and doubled the number of patients from whom lungs for transplant were harvested (lungs from 16 patients [27%] in the conventional strategy vs 32 patients [54%] in the protective strategy). Furthermore, although the numbers are small, there appears to be no detrimental effect of the protective strategy on transplant outcomes, either with the lungs or with other organs that were harvested at the same time. The secondary analyses provide evidence of a mechanistic reason as well. Levels of several inflammatory cytokines were significantly elevated among patients in the conventional strategy group.

These results are encouraging for several reasons. First, they demonstrate that in a cohort of patients who have already consented to be organ donors, the rate of viable organ procurement was doubled. In the context of lung transplantation, this has the potential to help eliminate the disparity between demand and supply. In 2009, 2234 candidates were added to the lung transplant waiting list and there were 1568 lung donors.¹ Doubling that donation rate could potentially meet steady-state demand as well as reduce waiting-list backlog, especially because each donor provides organs for more than 1 transplant. Second, although the sample size of the study by Mascia et al⁸ is small, there appears to be no detrimental effect on transplantation outcomes of either the transplanted lung or the other organs obtained from the donor. Third, this study has set the methodological bar regarding how such organ donor preservation studies should be conducted and demonstrated that such high-quality, controlled, and mechanistically informative studies are possible in the transplantation setting. However, the protective ventilation strategy is specific to lungs for transplantation, and further studies are needed to determine whether tailored preservation strategies will increase the viability of other organs.

The report by Halpern and colleagues⁷ evaluates the potential effect of a more complete use of organ donation af-

See also pp 2592 and 2620.

Author Affiliation: Department of Health Policy and Management, School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania.

Corresponding Author: Mark S. Roberts, MD, MPP, School of Public Health, University of Pittsburgh, 130 De Soto St, A621, Pittsburgh, PA 15261 (mroberts@pitt.edu).

ter circulatory determination of death (DCDD). There has been substantial debate regarding the value of organ DCDD because of the potential ethical dilemmas raised by this approach^{9,10} and because some evidence suggests that organs procured by DCDD protocols do not have the same viability as organs harvested after brain death.^{11,12} However, recent studies seem to imply equivalent survival in recipients.¹³⁻¹⁵ These arguments work against each other because the greater the elapsed time after circulatory cessation to ensure a permanent and defensible definition of death, the less viable the organ becomes.¹⁰ However, an Institute of Medicine report¹⁶ suggests that the use of organ DCDD is the most effective way of increasing donor supply.

Halpern et al⁷ analyzed nearly 40 000 in-hospital deaths in a large donor service area and found that less than 1% had potential for organ DCDD. Furthermore, the number of optimal organ DCDD (defined as donation of >1 optimal organ) would only provide 69 more donors (10.1%) than the number of donors identified after neurological determination of death, and 173 more suboptimal donors (25.3%) (defined as ineligible to donate optimal organs, but eligible to donate >1 suboptimal organ). Considering that the authors purposefully biased their analysis in favor of increasing the organ DCDD supply, these results likely represent an upper bound or at least an optimistic estimate for the potential of organ DCDD to expand the organ donor pool. For instance, in 2009, there were 8022 donors,¹ so that an increase in the donor pool through the optimal use of organ DCDD criteria would produce an estimated 800 to 2000 additional donors. This would be a welcome and important addition, but would not have the potential to eliminate the organ shortage.

Although any increase in viable organ donation will help, the report by Halpern et al⁷ cautions that reliance on the expansion of the donor pool through the use of organ DCDD will be insufficient to solve the problem of inadequate organ supply. The study by Mascia et al⁸ provides sobering evidence that conventional lung preservation practices, which have been used for many years, are remarkably inefficient in their task and that improved lung preservation strate-

gies can markedly increase the proportion of donated lungs that are transplanted. This article should provide encouragement to continue to apply such rigorous methods to improve the viability of potential donor organs and to take better care of the gift of life.

Financial Disclosures: None reported.

REFERENCES

1. US Dept of Health and Human Services; Organ Procurement and Transplantation Network. Organ Procurement and Transplantation Network data. <http://optn.transplant.hrsa.gov/latestData/viewDataReports.asp>. Accessed November 22, 2010.
2. Bosch X. Spain leads world in organ donation and transplantation. *JAMA*. 1999; 282(1):17-18.
3. Janssen A, Gevers S. Explicit or presumed consent and organ donation post-mortem: does it matter? *Med Law*. 2005;24(3):575-583.
4. DuBose J, Salim A. Aggressive organ donor management protocol. *J Intensive Care Med*. 2008;23(6):367-375.
5. Arnold R, Bartlett S, Bernat J, et al. Financial incentives for cadaver organ donation: an ethical reappraisal. *Transplantation*. 2002;73(8):1361-1367.
6. Mayrhofer-Reinhartshuber D, Fitzgerald A, Benetka G, Fitzgerald R. Effects of financial incentives on the intention to consent to organ donation: a questionnaire survey. *Transplant Proc*. 2006;38(9):2756-2760.
7. Halpern SD, Barnes B, Hasz RD, Abt PL. Estimated supply of organ donors after circulatory determination of death: a population-based cohort study. *JAMA*. 2010;304(23):2592-2594.
8. Mascia L, Pasero D, Slutsky AS, et al. Effect of a lung protective strategy for organ donors on eligibility and availability of lungs for transplantation: a randomized controlled trial. *JAMA*. 2010;304(23):2620-2627.
9. Obermann K, Nagel E, Pichlmayr R. Ethical considerations in procuring organs from non-heart-beating donors after sudden cardiac death. *Transplant Proc*. 1995; 27(5):2924-2925.
10. Halpern SD, Truog RD. Organ donors after circulatory determination of death: not necessarily dead, and it does not necessarily matter. *Crit Care Med*. 2010; 38(3):1011-1012.
11. Mason DP, Murthy SC, Gonzalez-Stawinski GV, et al. Early experience with lung transplantation using donors after cardiac death. *J Heart Lung Transplant*. 2008;27(5):561-563.
12. de Antonio DG, Marcos R, Laporta R, et al. Results of clinical lung transplant from uncontrolled non-heart-beating donors. *J Heart Lung Transplant*. 2007; 26(5):529-534.
13. Weber M, Dindo D, Demartines N, Ambühl PM, Clavien PA. Kidney transplantation from donors without a heartbeat. *N Engl J Med*. 2002;347(4):248-255.
14. Dubbeld J, Hoekstra H, Farid W, et al. Similar liver transplantation survival with selected cardiac death donors and brain death donors. *Br J Surg*. 2010; 97(5):744-753.
15. De Oliveira NC, Osaki S, Maloney JD, et al. Lung transplantation with donation after cardiac death donors: long-term follow-up in a single center. *J Thorac Cardiovasc Surg*. 2010;139(5):1306-1315.
16. Institute of Medicine Committee on Increasing Organ Donation. *Organ Donation: Opportunities for Action*. Washington, DC: National Academy Press; 2006.